{
  "success": true,
  "pagesUsed": [
    1,
    6,
    7,
    8,
    10,
    11,
    15,
    16,
    17,
    19,
    20,
    21,
    22,
    23
  ],
  "modelUsed": "gemini-3-flash-preview",
  "narrative": {
    "narrativeContents": [
      {
        "id": "nc_1",
        "name": "SYNOPSIS",
        "text": "SYNOPSIS",
        "order": 0,
        "instanceType": "NarrativeContent",
        "sectionNumber": "SYNOPSIS",
        "sectionTitle": "SYNOPSIS",
        "sectionType": {
          "id": "d572b219-72a2-46d4-80ec-1a4dec990157",
          "code": "Synopsis",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Synopsis",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_2",
        "name": "INTRODUCTION",
        "text": "INTRODUCTION",
        "order": 1,
        "instanceType": "NarrativeContent",
        "sectionNumber": "1",
        "sectionTitle": "INTRODUCTION",
        "sectionType": {
          "id": "a9ca2e1d-61a7-4f02-8ee1-b9cf13dc0823",
          "code": "Introduction",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Introduction",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_2_1",
          "nci_2_2",
          "nci_2_3",
          "nci_2_4",
          "nci_2_5"
        ]
      },
      {
        "id": "nc_3",
        "name": "OBJECTIVES AND HYPOTHESIS",
        "text": "OBJECTIVES AND HYPOTHESIS",
        "order": 2,
        "instanceType": "NarrativeContent",
        "sectionNumber": "2",
        "sectionTitle": "OBJECTIVES AND HYPOTHESIS",
        "sectionType": {
          "id": "e4ef1cc5-29b3-41d5-b805-8df4e4be766e",
          "code": "Objectives",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Objectives",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_3_1",
          "nci_3_2"
        ]
      },
      {
        "id": "nc_4",
        "name": "STUDY DESIGN AND RATIONALE",
        "text": "STUDY DESIGN AND RATIONALE",
        "order": 3,
        "instanceType": "NarrativeContent",
        "sectionNumber": "3",
        "sectionTitle": "STUDY DESIGN AND RATIONALE",
        "sectionType": {
          "id": "729dfc81-ecc2-41f5-934d-ffdfa2c0e51e",
          "code": "Study Design",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Design",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_4_1",
          "nci_4_2"
        ]
      },
      {
        "id": "nc_5",
        "name": "SUBJECT POPULATION",
        "text": "SUBJECT POPULATION",
        "order": 4,
        "instanceType": "NarrativeContent",
        "sectionNumber": "4",
        "sectionTitle": "SUBJECT POPULATION",
        "sectionType": {
          "id": "51061ea6-49c3-43a3-a02c-6d8d5b962e49",
          "code": "Study Population",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Population",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_5_1",
          "nci_5_2",
          "nci_5_3"
        ]
      },
      {
        "id": "nc_6",
        "name": "TREATMENT ALLOCATION AND BLINDING",
        "text": "TREATMENT ALLOCATION AND BLINDING",
        "order": 5,
        "instanceType": "NarrativeContent",
        "sectionNumber": "5",
        "sectionTitle": "TREATMENT ALLOCATION AND BLINDING",
        "sectionType": {
          "id": "e21abcd0-df5c-4764-a824-322013e28722",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        }
      },
      {
        "id": "nc_7",
        "name": "DOSAGE AND ADMINISTRATION",
        "text": "DOSAGE AND ADMINISTRATION",
        "order": 6,
        "instanceType": "NarrativeContent",
        "sectionNumber": "6",
        "sectionTitle": "DOSAGE AND ADMINISTRATION",
        "sectionType": {
          "id": "55654c6b-1314-43cc-9346-5156a4f4282e",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_7_1",
          "nci_7_2",
          "nci_7_3"
        ]
      },
      {
        "id": "nc_8",
        "name": "CONCOMITANT MEDICATIONS",
        "text": "CONCOMITANT MEDICATIONS",
        "order": 7,
        "instanceType": "NarrativeContent",
        "sectionNumber": "8",
        "sectionTitle": "CONCOMITANT MEDICATIONS",
        "sectionType": {
          "id": "5a13e6f8-797a-4f92-a2df-aa4e361d7edd",
          "code": "Treatment",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Treatment",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_8_1",
          "nci_8_2",
          "nci_8_3"
        ]
      },
      {
        "id": "nc_9",
        "name": "STUDY PROCEDURES",
        "text": "STUDY PROCEDURES",
        "order": 8,
        "instanceType": "NarrativeContent",
        "sectionNumber": "9",
        "sectionTitle": "STUDY PROCEDURES",
        "sectionType": {
          "id": "2e345f00-cf02-4bb9-b13d-a069c499ee03",
          "code": "Study Procedures",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Study Procedures",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_9_1",
          "nci_9_2",
          "nci_9_3",
          "nci_9_4"
        ]
      },
      {
        "id": "nc_10",
        "name": "SUBJECT COMPLETION/WITHDRAWAL",
        "text": "SUBJECT COMPLETION/WITHDRAWAL",
        "order": 9,
        "instanceType": "NarrativeContent",
        "sectionNumber": "10",
        "sectionTitle": "SUBJECT COMPLETION/WITHDRAWAL",
        "sectionType": {
          "id": "b0576c89-95d0-4d60-bb94-ae4be9d686fe",
          "code": "Other",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Other",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_10_1",
          "nci_10_2"
        ]
      },
      {
        "id": "nc_11",
        "name": "STATISTICAL METHODS",
        "text": "STATISTICAL METHODS",
        "order": 10,
        "instanceType": "NarrativeContent",
        "sectionNumber": "11",
        "sectionTitle": "STATISTICAL METHODS",
        "sectionType": {
          "id": "5277b75b-6275-480c-99d1-14b830548ec3",
          "code": "Statistics",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Statistics",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_11_1",
          "nci_11_2"
        ]
      },
      {
        "id": "nc_12",
        "name": "ADVERSE EVENT REPORTING",
        "text": "ADVERSE EVENT REPORTING",
        "order": 11,
        "instanceType": "NarrativeContent",
        "sectionNumber": "12",
        "sectionTitle": "ADVERSE EVENT REPORTING",
        "sectionType": {
          "id": "d918bfda-df45-48a9-8642-824479afec10",
          "code": "Safety",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Safety",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_12_1",
          "nci_12_2"
        ]
      },
      {
        "id": "nc_13",
        "name": "STUDY MANAGEMENT AND ETHICAL CONSIDERATIONS",
        "text": "STUDY MANAGEMENT AND ETHICAL CONSIDERATIONS",
        "order": 12,
        "instanceType": "NarrativeContent",
        "sectionNumber": "17",
        "sectionTitle": "STUDY MANAGEMENT AND ETHICAL CONSIDERATIONS",
        "sectionType": {
          "id": "aba6b34f-f26a-4e91-a4fa-d704af591965",
          "code": "Ethics",
          "codeSystem": "USDM",
          "codeSystemVersion": "2024-09-27",
          "decode": "Ethics",
          "instanceType": "Code"
        },
        "childIds": [
          "nci_13_1"
        ]
      }
    ],
    "narrativeContentItems": [
      {
        "id": "nci_2_1",
        "name": "Background",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.1",
        "sectionTitle": "Background"
      },
      {
        "id": "nci_2_2",
        "name": "Daratumumab",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.2",
        "sectionTitle": "Daratumumab"
      },
      {
        "id": "nci_2_3",
        "name": "Lenalidomide",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.3",
        "sectionTitle": "Lenalidomide"
      },
      {
        "id": "nci_2_4",
        "name": "Lenalidomide and Daratumumab",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.4",
        "sectionTitle": "Lenalidomide and Daratumumab"
      },
      {
        "id": "nci_2_5",
        "name": "Overall Rationale for the Study",
        "text": "",
        "order": 4,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "1.5",
        "sectionTitle": "Overall Rationale for the Study"
      },
      {
        "id": "nci_3_1",
        "name": "Objectives",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.1",
        "sectionTitle": "Objectives"
      },
      {
        "id": "nci_3_2",
        "name": "Hypothesis",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "2.2",
        "sectionTitle": "Hypothesis"
      },
      {
        "id": "nci_4_1",
        "name": "Overview of Study Design",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.1",
        "sectionTitle": "Overview of Study Design"
      },
      {
        "id": "nci_4_2",
        "name": "Study Design Rationale",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "3.2",
        "sectionTitle": "Study Design Rationale"
      },
      {
        "id": "nci_5_1",
        "name": "Inclusion Criteria",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.1",
        "sectionTitle": "Inclusion Criteria"
      },
      {
        "id": "nci_5_2",
        "name": "Exclusion Criteria",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.2",
        "sectionTitle": "Exclusion Criteria"
      },
      {
        "id": "nci_5_3",
        "name": "Prohibitions and Restrictions",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "4.3",
        "sectionTitle": "Prohibitions and Restrictions"
      },
      {
        "id": "nci_7_1",
        "name": "Daratumumab (Arm B Only)",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.1",
        "sectionTitle": "Daratumumab (Arm B Only)"
      },
      {
        "id": "nci_7_2",
        "name": "Lenalidomide (Arm A and Arm B)",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.2",
        "sectionTitle": "Lenalidomide (Arm A and Arm B)"
      },
      {
        "id": "nci_7_3",
        "name": "Dexamethasone (Arm A and Arm B)",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "6.3",
        "sectionTitle": "Dexamethasone (Arm A and Arm B)"
      },
      {
        "id": "nci_8_1",
        "name": "Permitted Therapies",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "8.2",
        "sectionTitle": "Permitted Therapies"
      },
      {
        "id": "nci_8_2",
        "name": "Prohibited Therapies",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "8.3",
        "sectionTitle": "Prohibited Therapies"
      },
      {
        "id": "nci_8_3",
        "name": "Subsequent Therapies",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "8.4",
        "sectionTitle": "Subsequent Therapies"
      },
      {
        "id": "nci_9_1",
        "name": "Overview",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "9.1",
        "sectionTitle": "Overview"
      },
      {
        "id": "nci_9_2",
        "name": "Efficacy",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "9.2",
        "sectionTitle": "Efficacy"
      },
      {
        "id": "nci_9_3",
        "name": "Pharmacokinetics and Immunogenicity",
        "text": "",
        "order": 2,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "9.3",
        "sectionTitle": "Pharmacokinetics and Immunogenicity"
      },
      {
        "id": "nci_9_4",
        "name": "Safety Evaluations",
        "text": "",
        "order": 3,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "9.8",
        "sectionTitle": "Safety Evaluations"
      },
      {
        "id": "nci_10_1",
        "name": "Completion",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "10.1",
        "sectionTitle": "Completion"
      },
      {
        "id": "nci_10_2",
        "name": "Discontinuation of Study Treatment",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "10.2",
        "sectionTitle": "Discontinuation of Study Treatment"
      },
      {
        "id": "nci_11_1",
        "name": "Sample Size Determination",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "11.2",
        "sectionTitle": "Sample Size Determination"
      },
      {
        "id": "nci_11_2",
        "name": "Efficacy Analysis",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "11.3",
        "sectionTitle": "Efficacy Analysis"
      },
      {
        "id": "nci_12_1",
        "name": "All Adverse Events",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "12.3.1",
        "sectionTitle": "All Adverse Events"
      },
      {
        "id": "nci_12_2",
        "name": "Serious Adverse Events",
        "text": "",
        "order": 1,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "12.3.2",
        "sectionTitle": "Serious Adverse Events"
      },
      {
        "id": "nci_13_1",
        "name": "Final OS Analysis/End of Study",
        "text": "",
        "order": 0,
        "instanceType": "NarrativeContentItem",
        "sectionNumber": "17.9.1",
        "sectionTitle": "Final OS Analysis/End of Study"
      }
    ],
    "abbreviations": [
      {
        "id": "abbr_1",
        "abbreviatedText": "CSR",
        "expandedText": "Clinical Study Report",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_2",
        "abbreviatedText": "OS",
        "expandedText": "Overall Survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_3",
        "abbreviatedText": "PD",
        "expandedText": "Disease Progression",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_4",
        "abbreviatedText": "DNA",
        "expandedText": "Deoxyribonucleic Acid",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_5",
        "abbreviatedText": "Dara-SC",
        "expandedText": "Daratumumab Subcutaneous",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_6",
        "abbreviatedText": "IV",
        "expandedText": "Intravenous",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_7",
        "abbreviatedText": "SC",
        "expandedText": "Subcutaneous",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_8",
        "abbreviatedText": "IRRs",
        "expandedText": "Infusion-Related Reactions",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_9",
        "abbreviatedText": "rHuPH20",
        "expandedText": "Recombinant Human Hyaluronidase PH20",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_10",
        "abbreviatedText": "PFS",
        "expandedText": "Progression Free Survival",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_11",
        "abbreviatedText": "DRd",
        "expandedText": "Daratumumab plus Rd",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_12",
        "abbreviatedText": "IDMC",
        "expandedText": "Independent Data Monitoring Committee",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_13",
        "abbreviatedText": "Rd",
        "expandedText": "Lenalidomide and Dexamethasone",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_14",
        "abbreviatedText": "IMWG",
        "expandedText": "International Myeloma Working Group",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_15",
        "abbreviatedText": "SAEs",
        "expandedText": "Serious Adverse Events",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_16",
        "abbreviatedText": "PFS2",
        "expandedText": "Progression-Free Survival after next line of therapy",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_17",
        "abbreviatedText": "PK",
        "expandedText": "Pharmacokinetics",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_18",
        "abbreviatedText": "ECOG",
        "expandedText": "Eastern Cooperative Oncology Group",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_19",
        "abbreviatedText": "ePRO",
        "expandedText": "Electronic Patient Reported Outcome",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_20",
        "abbreviatedText": "MRD",
        "expandedText": "Minimal Residual Disease",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_21",
        "abbreviatedText": "CR",
        "expandedText": "Complete Response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_22",
        "abbreviatedText": "sCR",
        "expandedText": "Stringent Complete Response",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_23",
        "abbreviatedText": "C1D1",
        "expandedText": "Cycle 1 Day 1",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_24",
        "abbreviatedText": "PCs",
        "expandedText": "Plasma Cells",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_25",
        "abbreviatedText": "FLC",
        "expandedText": "Free Light Chain",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_26",
        "abbreviatedText": "ICMJE",
        "expandedText": "International Committee of Medical Journal Editors",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_27",
        "abbreviatedText": "EOT",
        "expandedText": "End of Treatment",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_28",
        "abbreviatedText": "G-CSF",
        "expandedText": "Granulocyte Colony-Stimulating Factor",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_29",
        "abbreviatedText": "PBMCs",
        "expandedText": "Peripheral Blood Mononuclear Cells",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_30",
        "abbreviatedText": "MRU",
        "expandedText": "Medical Resource Utilization",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_31",
        "abbreviatedText": "eCRF",
        "expandedText": "Electronic Case Report Form",
        "instanceType": "Abbreviation"
      },
      {
        "id": "abbr_32",
        "abbreviatedText": "IHC",
        "expandedText": "Immunohistochemistry",
        "instanceType": "Abbreviation"
      }
    ],
    "summary": {
      "sectionCount": 13,
      "itemCount": 29,
      "abbreviationCount": 32
    },
    "studyDefinitionDocument": {
      "id": "sdd_1",
      "name": "A Phase 3, Randomized, Open-label Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) with Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Chemotherapy and Autologous Stem Cell Transplantation",
      "documentType": "Protocol",
      "language": "en",
      "instanceType": "StudyDefinitionDocument",
      "version": "Amendment 9",
      "versionDate": "20 July 2021",
      "contentIds": [
        "nc_1",
        "nc_2",
        "nc_3",
        "nc_4",
        "nc_5",
        "nc_6",
        "nc_7",
        "nc_8",
        "nc_9",
        "nc_10",
        "nc_11",
        "nc_12",
        "nc_13"
      ]
    }
  },
  "rawResponse": {
    "abbreviations": {
      "abbreviations": [
        {
          "abbreviation": "CSR",
          "expansion": "Clinical Study Report"
        },
        {
          "abbreviation": "OS",
          "expansion": "Overall Survival"
        },
        {
          "abbreviation": "PD",
          "expansion": "Disease Progression"
        },
        {
          "abbreviation": "DNA",
          "expansion": "Deoxyribonucleic Acid"
        },
        {
          "abbreviation": "Dara-SC",
          "expansion": "Daratumumab Subcutaneous"
        },
        {
          "abbreviation": "IV",
          "expansion": "Intravenous"
        },
        {
          "abbreviation": "SC",
          "expansion": "Subcutaneous"
        },
        {
          "abbreviation": "IRRs",
          "expansion": "Infusion-Related Reactions"
        },
        {
          "abbreviation": "rHuPH20",
          "expansion": "Recombinant Human Hyaluronidase PH20"
        },
        {
          "abbreviation": "PFS",
          "expansion": "Progression Free Survival"
        },
        {
          "abbreviation": "DRd",
          "expansion": "Daratumumab plus Rd"
        },
        {
          "abbreviation": "IDMC",
          "expansion": "Independent Data Monitoring Committee"
        },
        {
          "abbreviation": "Rd",
          "expansion": "Lenalidomide and Dexamethasone"
        },
        {
          "abbreviation": "IMWG",
          "expansion": "International Myeloma Working Group"
        },
        {
          "abbreviation": "SAEs",
          "expansion": "Serious Adverse Events"
        },
        {
          "abbreviation": "PFS2",
          "expansion": "Progression-Free Survival after next line of therapy"
        },
        {
          "abbreviation": "PK",
          "expansion": "Pharmacokinetics"
        },
        {
          "abbreviation": "ECOG",
          "expansion": "Eastern Cooperative Oncology Group"
        },
        {
          "abbreviation": "ePRO",
          "expansion": "Electronic Patient Reported Outcome"
        },
        {
          "abbreviation": "MRD",
          "expansion": "Minimal Residual Disease"
        },
        {
          "abbreviation": "CR",
          "expansion": "Complete Response"
        },
        {
          "abbreviation": "sCR",
          "expansion": "Stringent Complete Response"
        },
        {
          "abbreviation": "C1D1",
          "expansion": "Cycle 1 Day 1"
        },
        {
          "abbreviation": "PCs",
          "expansion": "Plasma Cells"
        },
        {
          "abbreviation": "FLC",
          "expansion": "Free Light Chain"
        },
        {
          "abbreviation": "ICMJE",
          "expansion": "International Committee of Medical Journal Editors"
        },
        {
          "abbreviation": "EOT",
          "expansion": "End of Treatment"
        },
        {
          "abbreviation": "G-CSF",
          "expansion": "Granulocyte Colony-Stimulating Factor"
        },
        {
          "abbreviation": "PBMCs",
          "expansion": "Peripheral Blood Mononuclear Cells"
        },
        {
          "abbreviation": "MRU",
          "expansion": "Medical Resource Utilization"
        },
        {
          "abbreviation": "eCRF",
          "expansion": "Electronic Case Report Form"
        },
        {
          "abbreviation": "IHC",
          "expansion": "Immunohistochemistry"
        }
      ]
    },
    "structure": {
      "document": {
        "title": "A Phase 3, Randomized, Open-label Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) with Lenalidomide and Dexamethasone (Rd) in Subjects with Previously Untreated Multiple Myeloma who are Ineligible for High-dose Chemotherapy and Autologous Stem Cell Transplantation",
        "version": "Amendment 9",
        "versionDate": "20 July 2021"
      },
      "sections": [
        {
          "number": "SYNOPSIS",
          "title": "SYNOPSIS",
          "type": "Synopsis"
        },
        {
          "number": "1",
          "title": "INTRODUCTION",
          "type": "Introduction",
          "subsections": [
            {
              "number": "1.1",
              "title": "Background"
            },
            {
              "number": "1.2",
              "title": "Daratumumab"
            },
            {
              "number": "1.3",
              "title": "Lenalidomide"
            },
            {
              "number": "1.4",
              "title": "Lenalidomide and Daratumumab"
            },
            {
              "number": "1.5",
              "title": "Overall Rationale for the Study"
            }
          ]
        },
        {
          "number": "2",
          "title": "OBJECTIVES AND HYPOTHESIS",
          "type": "Objectives",
          "subsections": [
            {
              "number": "2.1",
              "title": "Objectives"
            },
            {
              "number": "2.2",
              "title": "Hypothesis"
            }
          ]
        },
        {
          "number": "3",
          "title": "STUDY DESIGN AND RATIONALE",
          "type": "Study Design",
          "subsections": [
            {
              "number": "3.1",
              "title": "Overview of Study Design"
            },
            {
              "number": "3.2",
              "title": "Study Design Rationale"
            }
          ]
        },
        {
          "number": "4",
          "title": "SUBJECT POPULATION",
          "type": "Study Population",
          "subsections": [
            {
              "number": "4.1",
              "title": "Inclusion Criteria"
            },
            {
              "number": "4.2",
              "title": "Exclusion Criteria"
            },
            {
              "number": "4.3",
              "title": "Prohibitions and Restrictions"
            }
          ]
        },
        {
          "number": "5",
          "title": "TREATMENT ALLOCATION AND BLINDING",
          "type": "Treatment"
        },
        {
          "number": "6",
          "title": "DOSAGE AND ADMINISTRATION",
          "type": "Treatment",
          "subsections": [
            {
              "number": "6.1",
              "title": "Daratumumab (Arm B Only)"
            },
            {
              "number": "6.2",
              "title": "Lenalidomide (Arm A and Arm B)"
            },
            {
              "number": "6.3",
              "title": "Dexamethasone (Arm A and Arm B)"
            }
          ]
        },
        {
          "number": "8",
          "title": "CONCOMITANT MEDICATIONS",
          "type": "Treatment",
          "subsections": [
            {
              "number": "8.2",
              "title": "Permitted Therapies"
            },
            {
              "number": "8.3",
              "title": "Prohibited Therapies"
            },
            {
              "number": "8.4",
              "title": "Subsequent Therapies"
            }
          ]
        },
        {
          "number": "9",
          "title": "STUDY PROCEDURES",
          "type": "Study Procedures",
          "subsections": [
            {
              "number": "9.1",
              "title": "Overview"
            },
            {
              "number": "9.2",
              "title": "Efficacy"
            },
            {
              "number": "9.3",
              "title": "Pharmacokinetics and Immunogenicity"
            },
            {
              "number": "9.8",
              "title": "Safety Evaluations"
            }
          ]
        },
        {
          "number": "10",
          "title": "SUBJECT COMPLETION/WITHDRAWAL",
          "type": "Other",
          "subsections": [
            {
              "number": "10.1",
              "title": "Completion"
            },
            {
              "number": "10.2",
              "title": "Discontinuation of Study Treatment"
            }
          ]
        },
        {
          "number": "11",
          "title": "STATISTICAL METHODS",
          "type": "Statistics",
          "subsections": [
            {
              "number": "11.2",
              "title": "Sample Size Determination"
            },
            {
              "number": "11.3",
              "title": "Efficacy Analysis"
            }
          ]
        },
        {
          "number": "12",
          "title": "ADVERSE EVENT REPORTING",
          "type": "Safety",
          "subsections": [
            {
              "number": "12.3.1",
              "title": "All Adverse Events"
            },
            {
              "number": "12.3.2",
              "title": "Serious Adverse Events"
            }
          ]
        },
        {
          "number": "17",
          "title": "STUDY MANAGEMENT AND ETHICAL CONSIDERATIONS",
          "type": "Ethics",
          "subsections": [
            {
              "number": "17.9.1",
              "title": "Final OS Analysis/End of Study"
            }
          ]
        }
      ]
    }
  }
}